S&P 500   3,163.91 (+0.28%)
DOW   26,338.73 (+0.97%)
MSFT   205.71 (-0.66%)
GOOGL   1,502.34 (-0.65%)
BABA   244.76 (-2.75%)
GE   6.82 (+1.79%)
TSLA   1,502.52 (+0.36%)
T   29.91 (+0.47%)
ACB   11.74 (-2.81%)
F   6.30 (+3.62%)
GILD   76.32 (-0.47%)
DIS   118.39 (+1.85%)
BAC   23.93 (-1.12%)
S&P 500   3,163.91 (+0.28%)
DOW   26,338.73 (+0.97%)
MSFT   205.71 (-0.66%)
GOOGL   1,502.34 (-0.65%)
BABA   244.76 (-2.75%)
GE   6.82 (+1.79%)
TSLA   1,502.52 (+0.36%)
T   29.91 (+0.47%)
ACB   11.74 (-2.81%)
F   6.30 (+3.62%)
GILD   76.32 (-0.47%)
DIS   118.39 (+1.85%)
BAC   23.93 (-1.12%)
S&P 500   3,163.91 (+0.28%)
DOW   26,338.73 (+0.97%)
MSFT   205.71 (-0.66%)
GOOGL   1,502.34 (-0.65%)
BABA   244.76 (-2.75%)
GE   6.82 (+1.79%)
TSLA   1,502.52 (+0.36%)
T   29.91 (+0.47%)
ACB   11.74 (-2.81%)
F   6.30 (+3.62%)
GILD   76.32 (-0.47%)
DIS   118.39 (+1.85%)
BAC   23.93 (-1.12%)
S&P 500   3,163.91 (+0.28%)
DOW   26,338.73 (+0.97%)
MSFT   205.71 (-0.66%)
GOOGL   1,502.34 (-0.65%)
BABA   244.76 (-2.75%)
GE   6.82 (+1.79%)
TSLA   1,502.52 (+0.36%)
T   29.91 (+0.47%)
ACB   11.74 (-2.81%)
F   6.30 (+3.62%)
GILD   76.32 (-0.47%)
DIS   118.39 (+1.85%)
BAC   23.93 (-1.12%)
Log in

NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

$77.84
+0.48 (+0.62 %)
(As of 07/14/2020 12:05 PM ET)
Add
Compare
Today's Range
$77.45
Now: $77.84
$78.61
50-Day Range
$74.02
MA: $78.23
$82.90
52-Week Range
$65.25
Now: $77.84
$92.64
Volume2.52 million shs
Average Volume9.34 million shs
Market Capitalization$196.48 billion
P/E Ratio19.71
Dividend Yield3.18%
Beta0.48
Merck & Co., Inc. provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, thyroid, and cervical cancer, as well as brain tumors; and prevent diseases caused by human papillomavirus, as well as offers vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment and anthelmintic products; products to treat fleas and ticks in dogs and cats; fertility management products for horses; vaccines for dogs, cats, and horses; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with AstraZeneca PLC; Bayer AG; and Eisai Co., Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Read More
Merck & Co., Inc. logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.30 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP58933Y10
Phone908-740-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.84 billion
Cash Flow$6.79 per share
Book Value$10.21 per share

Profitability

Net Income$9.84 billion

Miscellaneous

Employees71,000
Outstanding Shares2,524,100,000
Market Cap$196.48 billion
Next Earnings Date7/31/2020 (Confirmed)
OptionableOptionable

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

How has Merck & Co., Inc.'s stock been impacted by COVID-19 (Coronavirus)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have decreased by 1.8% and is now trading at $77.84. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Merck & Co., Inc.?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for Merck & Co., Inc..

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Tuesday, April, 28th. The company reported $1.50 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.34 by $0.16. The business had revenue of $12.06 billion for the quarter, compared to the consensus estimate of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The firm's quarterly revenue was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $1.22 earnings per share. View Merck & Co., Inc.'s earnings history.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 26th. Investors of record on Monday, June 15th will be given a dividend of $0.61 per share on Tuesday, July 7th. This represents a $2.44 annualized dividend and a dividend yield of 3.13%. The ex-dividend date is Friday, June 12th. View Merck & Co., Inc.'s dividend history.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. announced that its Board of Directors has approved a stock repurchase plan on Thursday, October 25th 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 5.1% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its stock is undervalued.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2020 Pre-Market earnings guidance on Tuesday, April, 28th. The company provided earnings per share (EPS) guidance of 5.17-5.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $46.1-48.1 billion, compared to the consensus revenue estimate of $48.72 billion.

What price target have analysts set for MRK?

13 analysts have issued 12-month price targets for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.15 in the next year. This suggests a possible upside of 21.0% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

Has Merck & Co., Inc. been receiving favorable news coverage?

News stories about MRK stock have trended somewhat positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Merck & Co., Inc..

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a drop in short interest in June. As of June 30th, there was short interest totaling 14,560,000 shares, a drop of 7.9% from the June 15th total of 15,810,000 shares. Based on an average daily volume of 11,610,000 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.6% of the company's stock are short sold. View Merck & Co., Inc.'s Current Options Chain.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 64)
  • Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 52)
  • Ms. Jennifer L. Zachary, Exec. VP & Gen. Counsel (Age 41)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 67)
  • Mr. Adam H. Schechter, Special Advisor (Age 54)

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.10%), MERIAN GLOBAL INVESTORS UK Ltd (0.05%), Factory Mutual Insurance Co. (0.05%), Manning & Napier Group LLC (0.03%), Hexavest Inc. (0.03%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Hexavest Inc., Cacti Asset Management LLC, Centre Asset Management LLC, IFM Investors Pty Ltd, HNP Capital LLC, Exane Derivatives, and Municipal Employees Retirement System of Michigan. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, and Wendell P Weeks. View insider buying and selling activity for Merck & Co., Inc..

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, Canandaigua National Corp, DNB Asset Management AS, Whittier Trust Co., Fulton Bank N. A., Legacy Private Trust Co., and Watchman Group Inc.. View insider buying and selling activity for Merck & Co., Inc..

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $77.84.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $196.48 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.